Abstract Details

Title A Deep Dive into Brazilian's Epidemiological Landscape on Amyotrophic Lateral Sclerosis (ALS) in 2022

Topic General Neurology

Presentation(s) P6 - Poster Session 6 (11:45 AM-12:45 PM)

Poster/Presentation
Number 11-015

Objective Investigate the epidemiological characteristics and prevalence of outpatients with ALS in 2022 using data from public healthcare system secondary database (DATASUS) in Brazil.

Background Two drugs are approved for ALS treatment in Brazil: Riluzole, with access through the Brazilian public healthcare system (SUS), and Edaravone, accessed through out-of-pocket buy. The global prevalence is 3-5 per 100,000 population. A regional brazilian study in Porto Alegre city, estimated that the prevalence was similar to global data. There are global epidemiological studies, but in Brazil there is no nation-wide research.

Design/Methods We collected data from DATASUS medication dispensation module and mortality data was obtained from the DATASUS obituary database, both in 2022. The population collected was diagnosed with ALS, selected by ICD-10 G-12.2. Variables of Geographical Region, Sex, Age Group and Domestic Location were collected.

Results The database contains 46,276 records of 5,894 outpatients with ALS. The population was 56% male with a median age of 57 years old. Observing the Age Group of outpatients, 20% were between 0-49 years, 27% between 50-59 years, 32% between 60-69 years, and 21% were 70 years or older. Evaluating the Geographical Regions, a higher presence was observed in the Southeast region (51%), while the North region had the lowest percentage (4%). The common Domestic Location for medication dispensation were the capitals (53%). The national prevalence was 2.84, and the age-adjusted rate was 5.7 per 100,000 inhabitants and the mortality rate was 1.54.

Conclusions The study presents a comprehensive analysis of ALS prevalence and demographics in Brazil for 2022. The data highlights a national age-adjusted prevalence of 5.7 per 100,000 inhabitants, suggesting a higher prevalence on elderly Brazilians. An unusual behavior compared to global estimations. These findings underscore the importance of epidemiological research in Brazil to address public health challenges related to ALS.

Authors/Disclosures
Matheus Costa e Silva, BsC PRESENTER	Mr. Costa e Silva has received personal compensation for serving as an employee of Daiichi-Sankyo Brazil.
Julio H. Silva	Mr. Silva has nothing to disclose.
Juliana Argento de Sena (Daiichi Sankyo Brasil)	No disclosure on file
Fabiana Sanches, MD	Dr. Sanches has received personal compensation for serving as an employee of Daiichi Sankyo . Dr. Sanches has stock in Sanofi.
Ana Luiza M. Guerra	Miss Guerra has received personal compensation for serving as an employee of Daiichi Sankyo Brasil Farmaceutica Ltda .
Caio Huerta, MD	Mr. Huerta has received personal compensation for serving as an employee of Daiichi Sankyo.
Camila Higa	Mrs. Higa has nothing to disclose.
Renata G. Di Sessa, MD	Dr. Di Sessa has received personal compensation for serving as an employee of Daiichi Sankyo Brazil.
Leandro dos Santos	Mr. dos Santos has received personal compensation for serving as an employee of Daiichi Sankyo.
Carolina Guilhon, PhD	Mrs. Guilhon has received personal compensation for serving as an employee of Daiichi Sankyo.

��ɫ��

��ɫ��